Fudan-Zhangjiang Bio-Pharmaceutical

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Fudan-Zhangjiang Bio-Pharmaceutical , including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Fudan-Zhangjiang Bio-Pharmaceutical please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Fudan-Zhangjiang Bio-Pharmaceutical , including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Fudan-Zhangjiang Bio-Pharmaceutical please access Flcube.com

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio
CompanyDrug

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

HUTCHMED (China) Limited (NASDAQ: HCM, HKG: 0013) announced that it has initiated the Phase Ia portion of a global clinical trial evaluating HMPL-A830, a potential first‑in‑class antibody‑targeted conjugate (ATTC), for…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Shanghai Fudan-Zhangjiang Enrolls First Patient in U.S. Phase II Study for Port Wine Stain Treatment

CompanyDrug

Shanghai Fudan-Zhangjiang Enrolls First Patient in Phase III Trial for TROP2 ADC FDA018 in TNBC

CompanyDeals

Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo

CompanyDrug

Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization

CompanyDrug

Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors

CompanyDrug

Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis